Emerald Mutual Fund Advisers Trust Sells 346,387 Shares of Quanterix Co. (NASDAQ:QTRX)

Emerald Mutual Fund Advisers Trust cut its stake in Quanterix Co. (NASDAQ:QTRX - Free Report) by 61.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 216,860 shares of the company's stock after selling 346,387 shares during the quarter. Emerald Mutual Fund Advisers Trust owned about 0.56% of Quanterix worth $2,305,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of QTRX. Northern Trust Corp boosted its holdings in Quanterix by 5.6% in the fourth quarter. Northern Trust Corp now owns 366,164 shares of the company's stock valued at $3,892,000 after purchasing an additional 19,416 shares during the last quarter. Aquatic Capital Management LLC increased its position in Quanterix by 254.6% in the fourth quarter. Aquatic Capital Management LLC now owns 18,794 shares of the company's stock worth $200,000 after buying an additional 13,494 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Quanterix by 18.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 33,878 shares of the company's stock valued at $361,000 after purchasing an additional 5,385 shares during the period. Hsbc Holdings PLC grew its position in Quanterix by 25.8% in the 4th quarter. Hsbc Holdings PLC now owns 19,371 shares of the company's stock worth $205,000 after purchasing an additional 3,974 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Quanterix by 219.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock valued at $61,000 after buying an additional 3,915 shares during the last quarter. Hedge funds and other institutional investors own 86.48% of the company's stock.

Quanterix Trading Up 4.2 %

Quanterix stock traded up $0.24 during trading hours on Friday, reaching $6.01. 477,565 shares of the company were exchanged, compared to its average volume of 553,056. Quanterix Co. has a 12 month low of $4.67 and a 12 month high of $19.18. The stock has a 50-day moving average of $6.35 and a 200 day moving average of $9.30. The firm has a market cap of $233.12 million, a price-to-earnings ratio of -5.67 and a beta of 1.12.

Quanterix (NASDAQ:QTRX - Get Free Report) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.03). The company had revenue of $35.16 million during the quarter, compared to the consensus estimate of $34.93 million. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. As a group, research analysts forecast that Quanterix Co. will post -0.98 EPS for the current year.

Analysts Set New Price Targets

QTRX has been the subject of several recent analyst reports. Leerink Partnrs cut Quanterix from a "strong-buy" rating to a "hold" rating in a research note on Wednesday. Canaccord Genuity Group dropped their price target on Quanterix from $20.00 to $15.00 and set a "buy" rating on the stock in a research note on Tuesday, March 18th. Scotiabank restated an "outperform" rating on shares of Quanterix in a report on Tuesday, March 25th. Finally, Leerink Partners reiterated a "market perform" rating and issued a $8.00 target price (down previously from $12.00) on shares of Quanterix in a report on Wednesday. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $16.20.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.